Interim Report January – September 2018

BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects

Interim Report January – June 2018

Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease April – June 2018 Net revenues for the period amounted to SEK 52.3 ...

Interim Report January – March 2018

Continued progress of the project portfolio  January - March 2018 Net sales for the period amounted to SEK 52.3 million (26.2)  Operating profit amounted to SEK ...

BioArctic publishes the Annual Report for 2017

Stockholm, Sweden, April 24, 2018 – BioArctic AB (publ.) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2017 fiscal year has ...

NOTICE OF ANNUAL GENERAL MEETING IN BIOARCTIC AB (PUBL)

The shareholders in BioArctic AB (publ), corporate identity number 556601-2679, (”the Company”) are hereby summoned to the Annual General Meeting to be held on Tuesday, ...

Full Year Report January – December 2017

Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...

Interim Report January – September 2017

BioArctic listed on Nasdaq Stockholm Mid Cap. July - September 2017- Net sales for the period amounted to SEK 31.5 million (1.2). Operating profit amounted to SEK ...

Proud partner of: